Advancing Cancer Immunotherapy by Mitigating Immune-related Adverse Events (irAEs) (U01 Clinical Trial Not Allowed)
Closed Posted
- Opportunity number
- RFA-CA-19-044
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
-
- 93.121 Oral Diseases and Disorders Research
- 93.353 21st Century Cures Act - Beau Biden Cancer Moonshot
- 93.393 Cancer Cause and Prevention Research
- 93.846 Arthritis, Musculoskeletal and Skin Diseases Research
- 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research
- 93.855 Allergy and Infectious Diseases Research
- Funding instrument
- Cooperative Agreement
- Categories
-
- Education
- Food and Nutrition
- Health
- Eligible applicants
-
- Other
- City/Township Governments
- Small Businesses
- For Profit Organizations
- Special District Governments
- 501(c)(3) Nonprofits
- Independent School Districts
- Higher Education Inst. (Public)
- Public or Indian Housing Auth.
- State Governments
- County Governments
- Higher Education Inst. (Private)
- Tribal Organizations (Not Federally Recognized)
- Non-501(c)(3) Nonprofits
- Tribal Governments (Federally Recognized)
- Full announcement
Opportunity details come from Grants.gov. Updated .
Synopsis
This FOA will invite U01 applications in the specific area of cancer immunotherapy-related adverse events. Investigators are encouraged to submit applications that focus on mechanisms of immune reactivity/tolerance and/or autoimmune pathways that could be applied to improving immunotherapeutic approaches while simultaneously eliminating or reducing the severity of inflammatory or autoimmune responses. A related area of interest is studies designed to enhance the target specificity of immunotherapeutic reagents, to reduce or prevent irAEs. An additional synergistic focus of interest is the identification of predictive biomarkers of cancer patients at risk for developing irAEs. Understanding risk factors for developing an irAE would better inform patient stratification at the start of therapy and influence clinical monitoring. Achieving the goals of the RFA should establish a deeper understanding of the origins and activation pathways leading to inflammatory or autoimmune adverse events that currently limit the use of various immunotherapy regimens in patients.
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Files
| File | Type | Posted |
|---|---|---|
| PKG00248515-instructions.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity